Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kevin M KalinskyMelissa K AccordinoCodruta ChiuzanPrabhjot S MundiElizabeth SakachClaire SatheHeejoon AhnMeghna S TrivediYelena NovikAmy TierstenGeorge RaptisLea N BaerSun Y OhAmelia B ZelnakKari B WisinskiEleni AndreopoulouWilliam J GradisharErica M Stringer-ReasorSonya A ReidAnne O'DeaRuth M O'ReganKatherine D CrewDawn L HershmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2- MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.
Keyphrases
- epidermal growth factor receptor
- phase iii
- metastatic breast cancer
- open label
- tyrosine kinase
- placebo controlled
- double blind
- phase ii
- cell cycle
- advanced non small cell lung cancer
- clinical trial
- endothelial cells
- study protocol
- cell proliferation
- pluripotent stem cells
- protein kinase
- randomized controlled trial
- cell cycle arrest
- pi k akt